Showing posts sorted by date for query Aduhelm. Sort by relevance Show all posts
Showing posts sorted by date for query Aduhelm. Sort by relevance Show all posts

10 January 2023

Not This Shit Again

Once again, the FDA has approved a ruinously expensive Alzheimer's treatment based on dubious clinical data.

At this point, I have to figure that some senior folks at the FDA have a pecuniary interest in these products: 

The future of a new Alzheimer’s drug is unclear, even as the Food and Drug Administration granted fast-track approval to the treatment Friday afternoon.

The drug, which will be sold under the brand name Leqembi and priced at $26,500 per year, moderately slowed cognitive decline for patients with early stages of the disease. But some doctors and experts have been skeptical of the treatment, uncertain about its safety and whether it provides a substantial benefit.

Just so you know, the cost of $26,500.00 is  NOT a misplaced decimal point. 

………

This new dynamic comes in the shadow of intense criticism over the FDA’s decision in June 2021 to give fast-track approval to Aduhelm, a different drug developed by the same two companies, Eisai and Biogen. The debates over Alzheimer’s drugs have been particularly fraught as advocates push for treatments for a devastating disease that levies a harsh toll on patients and their loved ones.

Aduhelm showed no evidence of effectiveness at delaying cognitive decline, it just showed a reduction in plaques, which were thought, but have never been proven, to cause the disease, but increasingly seem to be a symptom.

………

The accelerated approval for Leqembi was based on a mid-stage trial that showed the treatment effectively removed a sticky protein from the brain, which is considered a hallmark of the illness. More recently, a larger trial found the drug — which is given intravenously twice a month — slowed the progression of Alzheimer’s by 27 percent, our colleague Laurie McGinley reports.

………

At least this one shows some positive results, though I'd bet dollars to navy beans that there was some manipulation of the study sample.

But others argue the risks outweigh the benefits. There are concerns over complications, such as swelling and bleeding in the brain. Such concerns have increased after Science and Stat reported that three patients died in incidents potentially linked to the drug, though the company’s CEO says he remains “confident of the safety profile” of the drug.

So, it makes your brain explode.  That can't be good. 

Seriously, has the FDA learned nothing from the Aduhelm fiasco?

10 October 2022

50 Years of Conventional Wisdom, Huh?

After almost a century of certainty that Amyloid Plaques cause Alzheimer's Disease, a new study shows that it is a lack of proteins, and not plaques, that cause the condition.

The general public did not start seeing these studies, and they tended not appear in the more prestigious journals until the drug Aduhelm crashed and burned in clinical tests, but was approved anyway. (At exorbitant cost)

Perhaps the outrage generated by this regulatory malpractice might have sent research in a new direction:

Contrary to a prevailing theory that has been recently called into question, new research from the University of Cincinnati (UC) bolsters a hypothesis that Alzheimer’s disease is caused by a decline in levels of a specific protein.

UC researchers led by Alberto Espay, MD, and Andrea Sturchio, MD, in collaboration with the Karolinska Institute in Sweden, published the research on October 4, 2022, in the Journal of Alzheimer’s Disease.

………

This research study was focused on a protein called amyloid-beta. The protein normally carries out its functions in the brain in a form that is soluble, meaning that it is dissolvable in water. However, it sometimes hardens into clumps, known as amyloid plaques.

For more than 100 years, the conventional wisdom in the field of Alzheimer’s research stated that Alzheimer’s was caused by the buildup of amyloid plaques in the brain. However, Espay and his colleagues hypothesized that plaques are actually just a consequence of the levels of soluble amyloid-beta in the brain decreasing. These levels decrease because the normal protein, under situations of biological, metabolic, or infectious stress, transforms into the abnormal amyloid plaques.

“The paradox is that so many of us accrue plaques in our brains as we age, and yet so few of us with plaques go on to develop dementia,” said Espay. He is a a UC Health physician, a professor of neurology in the UC College of Medicine, and director and endowed chair of the James J. and Joan A. Gardner Family Center for Parkinson’s Disease and Movement Disorders at the UC Gardner Neuroscience Institute. “Yet the plaques remain the center of our attention as it relates to biomarker development and therapeutic strategies.”

It should be noted that this sort of error, if it is actually an error, is not as uncommon as one would thing.  

For example, the number of chromosomes in a human cell was thought to be 48 for decades until advances in technology, particularly the use of colchicine, allowed for a definitive number, 46.

I think that one of the differences these days is the extraordinary, and excessive, profits in such treatments, which gives researchers a vested interest in not presenting heterodox theories.

Aduhelm cost $56,000.00 a year for treatment, and a new drug, mentioned in the study, lecanemab, has  a similar extortionate price, which means that the incentives to prostitute science for profit remain.

26 July 2022

It's the Corruption, Stupid

It turns out that the medical orthodoxy that amyloid plaques cause Alzheimer's disease are the product of fraud.

When I say that there is a problem with corruption in the sciences, and that this contributes to science denialism by much of the population, this is what I mean:

In short, Schrag has uncovered "anomalies" in the data at the heart of AD research that are the equivalent of discovering proof that mosquitoes had no role in spreading yellow fever. It also has put him in the middle of a controversy that has raged within the AD research community for decades, once thought to have been settled but which now seems primed to explode all over again.

………

If Schrag is right—and his research seems sound and his approach judicious—then we could be looking at one of the biggest and most important cases of bad science of all time. As I said, there always has been a raging argument over the role of beta-amyloid in AD. Is the protein the cause of the disease's devastating effects, or is it simply a marker of the disease's passage through the brain? (One opponent of the amyloid hypothesis explained his position by saying that the amyloid deposits were "like gravestones. They mark where the body is, but they're not what killed the person.") If the original basis for the amyloid hypothesis turns out to have been flawed, that would lead to the conclusion that billions of dollars have been wasted hunting snipes down blind alleys.

Not wasted, stolen.  If one looks at Aduhelm, cost $56,000.00 a year while providing no measurable improvement in cognitive function, someone is benefiting from this, it's just not patients or the public.

If you have to to wonder cui bono whenever you see a piece of potentially ground breaking research, you have a corruption problem in your field of study.

11 January 2022

Sucks to be Biogen

And this is a good thing.

As I  noted earlier Biogen managed to get FDA approval of their Alzheimer's Aduhelm treatment which is (at best) barely effective, and prices at $56,000 a year, (now on sale for only $28,000 a year) sparking huge outrage.

Well, now Medicare has ruled that it will only cover the drug for patients in clinical trials, meaning that the potential market will be a fraction of what was initially anticipated, saving Medicare tens of billions of dollars.

I like the way that they split the baby here:

Medicare officials on Tuesday proposed covering a pricey, controversial Alzheimer’s drug but, in a highly unusual step, restricted it to people enrolled in approved clinical trials, sharply limiting the number of eligible patients.

The draft decision from the Centers for Medicare and Medicaid Services (CMS) means the program would cover Aduhelm and similar drugs in development — monoclonal antibodies that target beta amyloid, a sticky substance in the brain — only in studies approved by CMS or supported by the National Institutes of Health. CMS almost never demands such trials for a drug already approved by the Food and Drug Administration.

………

The drug had been viewed as a potential blockbuster and budget buster. Biogen originally priced Aduhelm at $56,000 a year per patient, later cutting that to $28,200.

The only people who thought that this was a potential blockbuster were Biogen's accountants, everyone else thought that it was a disaster.

………

CMS officials, in a call with reporters explaining the tentative ruling, acknowledged the decision was unusual, but said it was appropriate.

“It’s important to recognize the FDA approved the drug under an accelerated approval program,” said Lee A. Fleisher, director of CMS’s center for clinical standards and quality. While the FDA found the drug safe, it based its conclusion about whether the drug worked not on its effect on patients but on its ability to reduce amyloid — something the FDA said had a reasonable likelihood of benefiting patients.

Fleisher noted that while the treatment might be promising, it also has the potential of seriously harming patients. Side effects include headaches, dizziness, falls and brain bleeds. He added that CMS believes “any appropriate assessment of patient outcomes must weigh both harm and benefits before arriving at a final decision.”

You know, if they had charged something like $5,600 a year, Biogen would be in fat city, at least until further studies showed that it has little or no effect, but they got greedy, and people noticed, and they got were made an example of.

We need more of this.

22 December 2021

Maybe the Good Guys Will Win This Time

Following a storm of criticism directed at the FDA for its approval of the Alzheimer's drug Aduhelm on the weakest of evidence, and a similar level of condemnation at Biogen's absurd price gouging, it appears that Biogen has been forced to cut the price of its drug in half, and even then almost no one is getting the prescribing the drug:

Biogen slashed the price of its controversial new Alzheimer’s drug Aduhelm on Monday as the drug faces weak sales and mounting criticism.

The price was reduced to $28,200 a year from $56,000 on the same day that a group of Alzheimer’s experts and health advocates called on the Food and Drug Administration to pull the drug off the market and said they were supporting an effort to file a formal petition with the agency to withdraw it.

“The F.D.A.’s decision to approve Aduhelm is indefensible in both scientific and clinical terms,” said a statement signed by 18 scientists, most of them doctors. “This drug should be withdrawn from the market immediately.”

The agency approved Aduhelm in June, even though a council of senior F.D.A. officials, an advisory committee of outside experts and many Alzheimer’s specialists said the scientific evidence showed that the drug did not provide a clear benefit to patients and that it carried risks of dangerous side effects.Major health systems, including Cleveland Clinic, Mount Sinai Health System, Mass General Brigham and the Department of Veterans Affairs have declined to offer Aduhelm, citing questions about its benefits and risks. In October, Biogen reported that Aduhelm had brought in just $1.9 million in revenue through September, a strikingly small amount given that about 1.5 million Americans have the mild Alzheimer’s-related dementia that makes them eligible for the drug.
Huh.  Let's run the numbers:  
  • $56,000.00 a year, so June through September would cost about $14,000.00.
  • Let's reduce this by 50% to account for people who got the drug later, and for profits of middlemen in the process, which gives us a cost per patient.
  • So, $1,900,000.00 ÷ $7,000.00 gives us 271 patients.

This is not what one would call a blockbuster.

………

But Brian Skorney, an analyst at Robert W. Baird & Company, said after the price announcement: “For the broad majority of people who are critical of Aduhelm, $56,000 and $28,000 are both exceptionally high prices for a drug that a lot of people perceive doesn’t work at all.”

The statement from Alzheimer’s experts and health advocates calling on the F.D.A. to withdraw Aduhelm grew out of a three-hour video meeting among the scientists last week.

“We’re not just saying the approval was probably the worst decision the F.D.A. ever made,” Dr. Peter Whitehouse, a neurologist and Alzheimer’s expert at Case Western Reserve University who led the Dec. 15 meeting, told attendees during the session. “It’s so bad that we should advocate for withdrawal.”

Ouch.

I get that Alzheimer's treatments are current mostly palliative, but approving the drug with little evidence of efficacy, and significant evidence that it cause things like brain bleeds, is simply irresponsible.

The FDA has been captured by big Pharma.